Expertise in
15
conditions

Dr. Russell J. Butterfield

University Of Utah Adult Services
Salt Lake City, UT
Expertise in
15
conditions
Specialties:Pediatric Neurology | Pediatrics | Neurology
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
OverviewInsuranceLocationsClinical Research

Overview

Russell Butterfield is a Pediatric Neurologist and a Pediatrics provider in Salt Lake City, Utah. Dr. Butterfield is highly rated in 15 conditions, according to our data. His top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD), and Spinal Muscular Atrophy (SMA). Dr. Butterfield is currently accepting new patients.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Neurology
Pediatrics
Neurology
Licenses
Neurology with Special Qualifications in Neurology in UT
Hospital Affiliations
University Of Utah Hospital And Clinics
Languages Spoken
English
Greek
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  BridgeSpan
  •  Cigna
  •  SelectHealth
  •  Regence
  •  Humana

Locations

UNIVERSITY OF UTAH ADULT SERVICES
50 N Medical Dr, Salt Lake City, UT 84132
801-581-2121

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial
Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Biological
Study Drug: CAP-1002 Allogeneic Cardiosphere-Derived Cells
Study Phase: Phase 2
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Enrollment Status: Terminated
Publish Date: January 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 15 Less Clinical Trials

61 Total Publications

Respiratory function and evaluation in individuals with facioscapulohumeral muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking and Research Network.
Respiratory function and evaluation in individuals with facioscapulohumeral muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking and Research Network.
Journal: Neuromuscular disorders : NMD
Published: June 17, 2024
Similar Doctors
Expertise in
15
conditions
Dr. Joshua L. Bonkowsky
Pediatric Neurology | Pediatrics | Neurology
Expertise in
15
conditions
Dr. Joshua L. Bonkowsky
Pediatric Neurology | Pediatrics | Neurology

University Of Utah Pediatric Services

81 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.2 mi)
801-213-3599
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Joshua Bonkowsky is a Pediatric Neurologist and a Pediatrics provider in Salt Lake City, Utah. Dr. Bonkowsky is highly rated in 15 conditions, according to our data. His top areas of expertise are CACH Syndrome, Adrenoleukodystrophy (ALD), Leukodystrophy, and Krabbe Disease. Dr. Bonkowsky is currently accepting new patients.

Expertise in
25
conditions
Dr. Howard Colman
Neurology | Neurosurgery
Expertise in
25
conditions
Dr. Howard Colman
Neurology | Neurosurgery

University Of Utah Acuity Care Services

175 N Medical Dr, U Of U Neuro Critical Care, 
Salt Lake City, UT 
 (0.1 mi)
801-585-7575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Howard Colman is a Neurologist and a Neurosurgery provider in Salt Lake City, Utah. Dr. Colman is highly rated in 25 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
1
conditions
Dr. Brandon A. Zielinski
Pediatric Neurology | Pediatrics | Neurology
Expertise in
1
conditions
Dr. Brandon A. Zielinski
Pediatric Neurology | Pediatrics | Neurology
100 Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.1 mi)
801-587-7575
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brandon Zielinski is a Pediatric Neurologist and a Pediatrics provider in Salt Lake City, Utah. Dr. Zielinski is highly rated in 1 condition, according to our data. His top areas of expertise are Autism Spectrum Disorder and Traumatic Brain Injury. Dr. Zielinski is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile